New Drug Approvals

Home » Uncategorized » Pamicogrel KB 3022 for Coagulation Disorders Therapy

Pamicogrel KB 3022 for Coagulation Disorders Therapy

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Archives

Categories

Recent Posts

Blog Stats

  • 4,479,759 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,841 other subscribers

add to any

Share

Pamicogrel
Pamicogrel
CAS  101001-34-7
D01090, TO-192, KBT-3022, KB-3022, Paminate, UNII-398FD8EDAL
2-[4,5-Bis(4-methoxyphenyl)-2-thiazolyl]-1H-pyrrole-1-acetic acid ethyl ester
Ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]-pyrrole-1-acetate
ethyl 2-[4,5-bis(p-methoxyphenyl)-2-thiazolyl]pyrrole-1-acetate
Manufacturers’ Codes: KB-3022; KBT-3022
Kanebo (Originator), Torii (Codevelopment)
Antiplatelet Therapy, Coagulation Disorders Therapy, HEMATOLOGIC DRUGS, Cyclooxygenase Inhibitors
Molecular Formula: C25H24N2O4S
Molecular Weight: 448.53
Percent Composition: C 66.94%, H 5.39%, N 6.25%, O 14.27%, S 7.15%
Properties: Crystals from ligroin, mp 132.5-135.5°.
Melting point: mp 132.5-135.5°
Toxicity data: LD50 orally in male mice: >3000 mg/kg (Yoshino)
Therap-Cat: Antithrombotic.
.PAMICOGREL

Pamicogrel (CAS NO.: 101001-34-7), with its systematic name of 1H-Pyrrole-1-acetic acid, 2-(4,5-bis(4-methoxyphenyl)-2-thiazolyl)-, ethyl ester, could be produced through many synthetic methods.

Following is one of the synthesis routes:
alpha-Bromo-4,4-dimethoxidesoxybenzoin (I) is cyclized with pyrrole-2-carbothioamide (II) in hot acetonitrile to produce 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazole (III), which is then condensed with ethyl bromoacetate (IV) in the prsence of NaOH and tetrabutylammonium bromide in refluxing dichloromethane – water.

The cyclization of alpha-bromo-4,4′-dimethoxydesoxybenzoin (I) with pyrrole-2-carbothioamide (II) in hot acetonitrile gives 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazole (III), which is then condensed with ethyl bromoacetate (IV) by means of NaOH and tetrabutylammonium bromide in refluxing dichloromethane – water
EP 0159677; JP 1985222481; JP 1986033186; JP 1986200985; US 4659726
pamicogrel
SYNTHESIS
    Reaction Scheme-I:

  • Figure imgb0005
    Figure imgb0006

    wherein R is as defined above, and Y is a halogen such as chlorine, bromine or iodine, or p-toluenesulfonyloxy group.

  • The process of the above reaction scheme-I can be carried out by reacting a compound (II) and an equimolar or excess amount of a compound (III) in the presence of a base or a phase transfer catalyst. In case of using a base such as metallic potassium, metallic sodium, potassium tert-butoxide etc.; the reaction is carried out in a solvent of tetrahydrofuran or dimethoxyethane at a temperature of from room temperature to a boiling point of the solvent for 1 to 24 hours. In case of using a phase transfer catalyst such as a quaternary ammonium salt (e.g. tetra-n-butylammonium bromide, methyltrioctylammonium chloride, etc.), the reaction is carried out in two phases of benzene or dichloromethane and 50 % aqueous sodium hydroxide or 60 % aqeuous potassium hydroxide at a temperature of from 0°C to a boiling point of the solvent for one minute to 24 hours.
    Reaction Scheme-II:

  • Figure imgb0007

    wherein X is a halogen such as bromine or chlorine.

  • The above process can be carried out by reacting a compound (IV) and an equimolar amount of a compound (V) in a solvent such as acetonitrile, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), or an alcohol (e.g. ethanol) at a temperature of from 50°C to a boling point of the solvent for 10 minutes to 4 hours.
    Reaction Scheme-III:

  • Figure imgb0008
    Figure imgb0009
    Reaction Scheme-IV:

  • Figure imgb0010

    wherein R1 is as defined above.

  • The process can be carried out by converting a compound (VII) into an oxime (VIII) by a conventional oxime forming reaction, heating the oxime (VIII) in acetic anhydride to obtain a compound (IX), and treating the compound (IX) with hydrogen sulfide, that is, by blowing hydrogen sulfide gas into a reaction system containing the compound (IX) in a solvent such as DMF, DMSO or pyridine in the presence of 0.5 to 5 equimolar amount of a base such as a tertiary amine (e.g. triethylamine) at a temperature of from 0° to 40°C for 3 to 24 hours
    Reaction Scheme-V:

  • Figure imgb0011
    Reference Example 6
    4,5-Bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazole [compound of the formula (II)]:
  • Pyrrole-2-carbothioamide (cf. J. Org. Chem., 38, 667, 1973) (1.51 g, 12 mmole) and α-bromo-4,4′-dimethoxy- deoxybenzoin (cf. Aust. J. Chem., 8, 385. 1955) (4.02 g, 12 mmole) are dissolved in acetonitrile (120 ml). The mixture is stirred at 60°C for 50 minutes. After the reaction, the reaction mixture is distilled under reduced pressure to remove the solvent. To the resulting residue are added chloroform and aqueous solution of sodium carbonate, and the mixture is shaken. The chloroform layer is taken, and the aqueous layer is further extracted with chloroform. The chloroform layers are combined, dried over anhydrous magnesium sulfate, and distilled under reduced pressure to remove the solvent. The residue is recrystallized from ligroin to give 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)-thiazole (3.74 g, yield: 86 %).
  • M.p. 131.5 – 134.0°C
  • NMR (CDCl3, δ ppm): 3.7 (6H) , 6.1 (1H, dd) , 6.5-6.9 (6H), 7.1-7.5 (4H), 9.4-9.8 (lH).
  • Elementary analysis for C21H18N2O2S:

    Figure imgb0016
    Example 14

  • Ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]-pyrrole-1-acetate (compound of the formula (I) wherein R1 = -CH2-COOC2H5):

    • 4,5-Bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazole obtained in the same manner as described in Reference Example 6 (3.62 g, 10 mmole), ethyl bromoacetate (1.67 g, 10 mmole), and tetra-n-butylammonium bromide (0.32 g, 1 mmole) are refluxed with vigorous stirring in two phases of dichloromethane (40 ml) and 50 % aqueous sodium hydroxide (40 ml) at room temperature for 2 minutes. To the mixture are added water and dichloromethane under ice-cooling, and the mixture is shaken. The dichloromethane layer is taken, and the aqueous layer is further extracted with dichloromethane. The dichloromethane layers are combined, dried over anhydrous magnesium sulfate, and distilled under reduced pressure to remove the solvent. The residue is recrystallized from ligroin to give ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]pyrrole-1-acetate (3.64 g, yield: 81 %).
  • M.p. 132.5 – 135.5°C
  • NMR (CDCl3, δ ppm): 1.2 (3H, t), 3.8 (6H), 4.15 (2H, q), 5.25 (2H, s), 6.25 (1H, dd), 6.7-6.95 (6H), 7.2-7.55 (4H).
  • Elementary analysis for C25H24N2O4S:

    Figure imgb0026
Literature References:
Cyclooxygenase inhibitor. Prepn: K. Yoshino et al., EP 159677eidem, US 4659726 (1985, 1987 both to Kanebo).
Drugs Fut1991,16,(2):105
Chemical and Pharmaceutical Bulletin, 1992 ,  vol. 40,  11  pg. 3048 – 3051
HPLC determn in plasma and urine: Y. Nakada et al., Chem. Pharm. Bull. 38, 1093 (1990).
Pharmacokinetics: Y. Nakada et al., Yakuzaigaku 53, 210 (1993), C.A. 120, 315100 (1993).
Activity as antithrombotic: K. Yokoto et al., Jpn. J. Pharmacol. 68, 201 (1995); as platelet aggregation inhibitor: K. Yokoto et al., J. Pharm. Pharmacol. 47, 768 (1995).
Evaluation of cerebral protective effects: N. Yamamoto et al., Jpn. J. Pharmacol. 69, 421 (1995); eidem, Eur. J. Pharmacol. 297, 225 (1996).

Determination of the antiplatelet agent. KB-3022, and its metabolite by high-performance liquid chromatography.Nakada Y, Ikuta Y, Kawashima T, Awata N.Chem Pharm Bull (Tokyo). 1990 Apr;38(4):1093-5.

pamicogrel
PATENTS
EP0037274A1 * 30 Mar 1981 7 Oct 1981 Eli Lilly And Company Substituted triaryl thiazole compounds
EP0077024A2 * 7 Oct 1982 20 Apr 1983 Schering Aktiengesellschaft Imidazole derivatives, process for their preparation and pharmaceutical products containing them
US4168315 * 28 Sep 1977 18 Sep 1979 The Upjohn Company Dianisyl thiazole compound, compositions and method of antithrombotic treatment

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,841 other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Personal Links

View Full Profile →

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.